| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 161 | INSECTICIDAL BIPHENYLTHIOHYDRAZIDES | PCT/US2001/018237 | 2001-06-05 | WO2002098841A1 | 2002-12-12 | DIEHL, Robert, E.; HUNT, David, Allen; TROTTO, Susan, Hensen |
The present invention provides N-biphenylthiohydrazone derivatives of formula (I) and compositions and methods for the use thereof in the control of insect and acarid pests and for the protection of crops therefrom. |
||||||
| 162 | METHOD FOR STEREOSELECTIVELY PRODUCING HYDRAZINO CYCLOALKENES AND DIAMINO CYCLOALKANES | PCT/EP2001/012324 | 2001-10-25 | WO02036548A2 | 2002-05-10 | |
| The invention relates to a novel method for carrying out the stereoselective, palladium-catalyzed production of hydrazino cycloalkenes of general formula (Ia) and of diamino bicycloalkanes of general formula (IV), in which A, R<1>, R<2>, R<3> and R<4> have the meanings cited in the description. The invention also relates to compounds that can be obtained according to the method. | ||||||
| 163 | VERFAHREN ZUR HERSTELLUNG VON DNDA | PCT/EP2001/010023 | 2001-08-30 | WO2002026692A3 | 2002-04-04 | SCHIRRA, Rainer; EMANS, Heinz-Gerd; LICHTBLAU, Leonard |
Die vorliegende Erfindung beschreibt ein ölonomisch, chemisch und verfahrenstechnisch sinnvolles Verfahren zur Herstellung von DNDA. |
||||||
| 164 | NOVEL TOPOISOMERASE POISONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | PCT/US2000/030804 | 2000-11-10 | WO01034151A1 | 2001-05-17 | |
| Methods for the treatment of a proliferative disorder are provided in which a subject in need of such treatment is administered an effective amount of a compound selected from: compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein X<1> and X<2> are independently H, Cl, F, Br, I, CN, CF3 or NO2, and Ar<1> is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and compounds of formula (II) wherein X<3> and X<4> are each independently H, Cl, F, Br, I, CN, CF3 or NO2; Y is (C2-C6)alkylene or (C2-C6)heteroalkylene; and Z is Cl, F, Br, I, CN, CF3 or NO2. | ||||||
| 165 | PROCESS OF PREPARING A HIGH-ENERGY SOFTENING AGENT | PCT/NO1999/000312 | 1999-10-14 | WO01027073A1 | 2001-04-19 | |
| The present invention relates to a continuous process of preparing N-alkyl-nitratoethylamines and a production plant for carrying out a continuous process of preparing such N-alkyl-nitratoethylamines. | ||||||
| 166 | PHENYLALANINOL DERIVATIVES | PCT/EP2000/001168 | 2000-02-12 | WO00048988A1 | 2000-08-24 | |
| Compounds of formula (1) and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined in the specification, are effective inhibitors of the binding of VCAM-1 to VLA-4 in vivo and are useful in treating inflammation in inflammatory diseases in which such binding acts to bring on the inflammation. | ||||||
| 167 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | PCT/US1999/007723 | 1999-04-08 | WO99053039A1 | 1999-10-21 | |
| The present invention relates to compounds and pharmaceutical compositions which inhibit proteases, such as cysteine proteases. In particular, the present invention relates to compounds and pharmaceutical compositions which inhibit cysteine proteases of the papain superfamily. The compounds and pharmaceutical compositions of the present invention are useful for treating diseases, particularly parasitic diseases, which are mediated by such proteases. In particular, the present invention relates to a method of treating malaria by inhibiting the cysteine protease falcipain. | ||||||
| 168 | IL-8 RECEPTOR ANTAGONISTS | PCT/US1998/015830 | 1998-07-29 | WO99006354A1 | 1999-02-11 | |
| This invention relates to novel phenyl ureas useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). | ||||||
| 169 | NOVEL COMPOUNDS | PCT/US1998/005709 | 1998-03-20 | WO98042656A1 | 1998-10-01 | |
| The present invention is directed to compounds of formula (1) and pharmaceutically-acceptable derivatives thereof. | ||||||
| 170 | HEXASUBSTITUTED CYCLOHEXANE COMPOUNDS | PCT/EP8700318 | 1987-06-19 | WO8800940A2 | 1988-02-11 | PRAEFCKE KLAUS; KOHNE BERND; DORSCH DIETER; RIEGER BERNHARD |
| Hexasubstituted cyclohexane compounds which are suitable as components of discotic liquid crystal phases. | ||||||
| 171 | VINYL COMPOSITIONS | PCT/EP8600754 | 1986-12-16 | WO8704426A3 | 1987-10-22 | WAECHTLER ANDREAS; KRAUSE JOACHIM; EIDENSCHINK RUDOLF; SCHEUBLE BERNHARD; HITTICH REINHARD |
| Vinyl compositions having formula (I): R1-(A1-Z1)m-(A2-Z2)n-(A3)o-Q-CH=CH-R2, in which R1, R2, A1, A2 and A3, Z1 and Z2, m and o, n, Q and p have the definitions given in claim 1, are useful as components of liquid crystal phases. | ||||||
| 172 | SYNTHETIC ROUTES TO CYCLOPENTANECARBOXYLIC ACID DERIVATIVES | PCT/EP8600678 | 1986-11-25 | WO8703278A2 | 1987-06-04 | NUMMY LAURENCE JOHN; CORKINS H GLENN; SCARANO LOUIS S; BYRNE DENNIS P |
| A ring contraction approach is applied to preparation of cyclopentane derivatives, especially 2,2,5,5-tetra-methylcyclopentanecarboxylic acid from cyclohexane compounds. In one aspect, a cyclohexane diazoketone is reacted with an amine (e.g., an alanine ester) to form the corresponding cyclopentane acid amide. | ||||||
| 173 | PROCESS FOR THE CYCLOPROPANATION OF OLEFINS USING N-METHYL-N-NITROSO COMPOUNDS | US16731361 | 2019-12-31 | US20200172453A1 | 2020-06-04 | Fridtjof SCHRÖDER; Marcel STECK |
| A process of converting a carbon-carbon double bond on a substrate into a cyclopropane ring, which method comprises the step of treating the substrate with a N-alkyl-N-nitroso compound, a transition metal catalyst and an aqueous base, wherein the N-alkyl-N-nitroso compound is formed by reacting an alkyl amine with an alkali metal nitrite in the presence of a mono-basic or di-basic acid, or a mixture thereof, and wherein the N-alkyl-N-nitroso compound is not distilled before it is mixed with the substrate, catalyst and base. | ||||||
| 174 | Process for the cyclopropanation of olefins using N-methyl-N-nitroso compounds | US15758795 | 2016-09-14 | US10611704B2 | 2020-04-07 | Fridtjof Schröder; Marcel Steck |
| A process of converting a carbon-carbon double bond on a substrate into a cyclopropane ring, which method comprises the step of treating the substrate with a N-alkyl-N-nitroso compound, a transition metal catalyst and an aqueous base, wherein the N-alkyl-N-nitroso compound is formed by reacting an alkyl amine with an alkali metal nitrite in the presence of a mono-basic or di-basic acid, or a mixture thereof, and wherein the N-alkyl-N-nitroso compound is not distilled before it is mixed with the substrate, catalyst and base. | ||||||
| 175 | Process for the preparation of N-alkyl-nitratoethylnitramines | US16353735 | 2019-03-14 | US20190284131A1 | 2019-09-19 | Anian NIEDER; Tobias WUENSCHE; Anne Theresa FRIEDRICHS; Johannes KAINZ; Alexander HUBER |
| The present invention relates to a continuous process for the preparation of N-alkyl-nitratoethylnitramines (e.g. NENA compounds, DINA). | ||||||
| 176 | TRIFLUOROACETYL HYDRAZIDE COMPOUNDS AND MEDICAL USES THEREOF | US16501284 | 2019-03-19 | US20190218192A1 | 2019-07-18 | Yuqiang Wang; Haiyun Chen; Zaijun Zhang; Gaoxiao Zhang; Pei Yu; Yewei Sun; Luchen Shan; Liang Tao |
| The present invention relates to trifluoroacetyl hydrazide compounds and medical uses thereof. The compounds have a structure of the following formula: The compounds showed multifunctional mechanisms, including inhibition of glutamate excitotoxicity, activation of MEF2 transcriptional activity, clearance of free radicals, and promotion of nerve differentiation, and has a better protective effect on cells especially nerve cells. The compound can be used to prepare prophylactic or therapeutic medicaments with cytoprotective effects, for the prevention or treatment of diseases related to glutamate receptor activation, MEF2 disorders or excessive free radicals generation. The diseases include, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson and stroke, and the free radicals related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases. | ||||||
| 177 | Trifluoroacetyl hydrazide compounds and methods of preparation and uses thereof | US15731538 | 2015-08-11 | US10308616B2 | 2019-06-04 | Yuqiang Wang; Haiyun Chen; Zaijun Zhang; Gaoxiao Zhang; Pei Yu; Yewei Sun; Luchen Shan; Liang Tao |
| The present invention relates to trifluoroacetyl hydrazide compounds and methods of preparation and uses thereof. The compounds have a structure of the following formula: The compounds showed multifunctional mechanisms, including inhibition of glutamate excitotoxicity, activation of MEF2 transcriptional activity, clearance of free radicals, and promotion of nerve differentiation, and has a better protective effect on cells especially nerve cells. The compound can be used to prepare prophylactic or therapeutic medicaments with cytoprotective effects, for the prevention or treatment of diseases related to glutamate receptor activation, MEF2 disorders or excessive free radicals generation. The diseases include, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson and stroke, and the free radicals related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases. | ||||||
| 178 | METHOD FOR THE PREPARATION OF DIAZOALKANES | US14373828 | 2013-01-23 | US20150038687A1 | 2015-02-05 | Lee Proctor |
| The present invention relates to a method of forming diazoalkanes. One aspect of the present invention provides a method for the production of a N-alkyl-N-nitroso compound from a starting material, comprising the use of a tribasic acid to acidify an amine. A second aspect of the present invention provides a method for the production of a diazoalkane, comprising reacting a N-alkyl-N-nitroso compound with a base and a phase transfer catalyst, wherein no organic solvent is used. | ||||||
| 179 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | US12933196 | 2009-03-17 | US08895776B2 | 2014-11-25 | Thuy-Anh Tran; Weichao Chen; Bryan A. Kramer; Abu J. M. Sadeque; Anna Shifrina; Young-Jun Shin; Pureza Vallar; Ning Zou |
| The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD). | ||||||
| 180 | Method for preparing ramalin | US13810145 | 2011-07-14 | US08865934B2 | 2014-10-21 | Joung Han Yim; Il Chan Kim; Sung Gu Lee; Dockyu Kim; Se Jong Han; Hyoung Seok Lee; Seung Jin Kim; Tai Kyoung Kim; Pil-Sung Kang; Heeyong Park; Ha Ju Park; Hye Yeon Koh; Mi Ra Park; Yu-Kyeong Park |
| The present invention relates to a method for synthesizing ramalin, and more particularly to a method for synthesizing ramalin, which comprises allowing 2-hydrazinylphenol to react with L-glutamic acid having a protected carboxyl group at C-1 and a protected amino group at C-2, and a method for preventing decomposition of the ramalin. According to the present invention, ramalin having excellent antioxidant and anti-inflammatory activities can be synthesized in high yield, and thus can be produced in large amounts. In addition, ramalin can be stably maintained for a long period of time, and thus can be easily used for industrial purposes. | ||||||
QQ群二维码
意见反馈
意见反馈